English
Spanish
Italian
French
Greek
Portuguese
Japanese
Danish
Dutch
Finnish
Croatian
Estonian
Filipino
Czech
Korean
Slovenian
Chinese (Simplified)
Chinese (Traditional)
Somali
Hebrew
Polish
Hindi
Hungarian
Slovak
Norwegian
Swedish
Persian
Romanian
Punjabi
Arabic
Ukrainian
Russian
Bulgarian
Indonesian
Bosnian
Afrikaans
Armenian
AlbanianThe dietary supplement industry has been begging for federal oversight of products containing cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant that is being incorporated into a bewildering range of oils, tinctures, edibles, and other products. Certification by the Food and Drug Administration that these products are safe and useful against many common ailments could unleash a $60 billion annual market by 2030.
But the Useless FDA turned down industry trade groups, and for good reason. Regulators can set standards only for products they understand, and right now the evidence on CBD safety is thin to nonexistent, and is similarly speculative on its effectiveness.
Click this link for the original source of this article.
Author: Rosalie Liccardo Pacula
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
